Manipal Health Enterprises, which operates Manipal Hospitals, has successfully repaid ₹5,310 crore of its debt using funds raised from its recent Initial Public Offering (IPO). This significant financial maneuver is expected to substantially reduce the company’s interest burden and provide greater flexibility for strategic investments in expansion, technology, and talent development.
Strategic Debt Repayment Post-IPO
The repayment specifically targeted and fully redeemed listed non-convertible debentures (NCDs) worth ₹5,310 crore, which were issued by its wholly-owned subsidiary, Manipal Hospitals Private Limited. This action aligns with the plan detailed in Manipal Health’s IPO prospectus dated July 31, 2026, and included the outstanding NCD principal, accrued interest, and any applicable prepayment or early redemption costs.
Commenting on the redemption, Sameer Agarwal, Chief Financial Officer, Manipal Health Enterprises, stated, “By deploying the IPO proceeds towards debt repayment as planned, we are strengthening our balance sheet, reducing our interest burden and creating greater financial headroom to support our growth plans. This gives us greater flexibility to continue investing in capacity, technology and talent while remaining focused on delivering quality and affordable healthcare.”
The company anticipates that this reduction in debt will enhance its financial stability, support profitable growth, and improve operational efficiency across its extensive network.
Manipal Hospitals Network and Recent Performance
Manipal Hospitals boasts a robust network comprising 50 multispecialty hospitals. These facilities collectively offer over 13,000 licensed beds across 14 states and union territories. The healthcare provider is supported by a dedicated team of more than 11,000 doctors and 25,000 employees, serving over 7 million patients annually.
In its first quarter of fiscal year 2027 (Q1 FY27), Manipal Health Enterprises reported a 7.7% year-on-year decline in net profit, reaching ₹231 crore compared to ₹250 crore in the same period last year. Despite this, the company saw a significant 38.1% rise in revenue, climbing to ₹3,091 crore from ₹2,238 crore. Earnings before interest, tax, depreciation, and amortisation (EBITDA) also increased by 25.6% to ₹736.5 crore, up from ₹586.5 crore, although the EBITDA margin narrowed slightly to 23.8% from 26.2% a year earlier.
Shares of Manipal Health Enterprises concluded trading at ₹736.55 on the National Stock Exchange, marking a 2.08% increase from its previous close.